Company to leverage capital and Valor's expertise for strategic initiatives building market awareness, R&D roadmap, data analysis capabilities, and expanding access to Deep TMS™ Purchase price of US$9.51 represents a 20% premium over 30-day VWAP of BrainsWay's American Depositary Shares Valor provides growth equity to technology-enabled companies and currently has $18.9B in assets under management BURLINGTON, Mass. and JERUSALEM, Sept. 30, 2024 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) ("Brai ...

While "the trend is your friend" when it comes to short-term investing or trading, timing entries into the trend is a key determinant of success. And increasing the odds of success by making sure the sustainability of a trend isn't easy. The trend often reverses before exiting the trade, leading to a short-term capital loss for investors. So, for a profitable trade, one should confirm factors such as sound fundamentals, positive earnings estimate revisions, etc. that could keep the momentum in the stock ali ...

BURLINGTON, Mass. and JERUSALEM, Sept. 16, 2024 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) ("BrainsWay" or the "Company"), a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, today announced the expansion of its Deep TMS™ platform along the East Coast of the U.S. through the recent order of 14 new systems by a large and growing enterprise network. The large order follows other recent multisystem orders placed with the Company, further strengthening ...

Core Viewpoint - BrainsWay Ltd. has received approval from the Israel Ministry of Defense for the reimbursement of its Deep Transcranial Magnetic Stimulation (Deep TMS™) therapy for patients with post-traumatic stress disorder (PTSD) in Israeli public hospitals, marking a significant step in addressing the mental health crisis exacerbated by recent conflicts in the region [1][3]. Company Overview - BrainsWay is a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, utilizing its proprietary Deep TMS™ technology to improve health outcomes [5]. - The company has obtained three FDA-cleared indications for its TMS technology, which include major depressive disorder, obsessive-compulsive disorder, and smoking addiction [5]. - Founded in 2003, BrainsWay operates from Burlington, MA, and Jerusalem, Israel, and is focused on expanding global awareness and access to Deep TMS [5]. Industry Context - The prevalence of PTSD in Israel is a growing concern, particularly following the October 7th Hamas-led attacks, with estimates suggesting that over 5% of the population may develop PTSD [4]. - A recent study involving 99 military veterans treated with Deep TMS showed significant reductions in PTSD symptoms (44.1%), depression (43.5%), and suicidal ideation (54%) after six months [4]. Future Directions - The company aims to expand the reimbursement program for PTSD treatment to include more medical centers and private clinics in Israel [2]. - Although Deep TMS is not yet FDA-cleared for PTSD treatment, the reimbursement program is expected to facilitate the collection of additional efficacy and safety data to support future applications [6].

Investors prefer to put their money in businesses that reap profits on a regular basis. In order to gauge the extent of profits, there is no better metric than net profit margin. A higher net margin reflects a company's efficiency in converting sales into actual profits. BrainsWay Ltd. (BWAY) , Qifu Technology, Inc. (QFIN) , Great Lakes Dredge & Dock Corporation (GLDD) and The Gorman-Rupp Company (GRC) boast solid net profit margins. Net Profit Margin = Net profit/Sales * 100. In simple terms, net profit is ...

Core Viewpoint - The article emphasizes the importance of identifying and maintaining stock price trends for successful short-term investing, highlighting the utility of a specific screening strategy to find stocks with strong fundamentals and positive momentum. Group 1: Stock Price Trends - The "Recent Price Strength" screen helps identify stocks with sufficient fundamental strength to sustain their recent upward trends [3] - Brainsway Ltd. (BWAY) has shown a solid price increase of 22.8% over the past 12 weeks, indicating investor confidence [4] - A recent price increase of 16.8% over the last four weeks further confirms that the upward trend for BWAY is intact [5] - BWAY is currently trading at 92.9% of its 52-week high-low range, suggesting a potential breakout [5] Group 2: Fundamental Strength - BWAY holds a Zacks Rank 1 (Strong Buy), placing it in the top 5% of over 4,000 ranked stocks based on earnings estimate revisions and EPS surprises [6] - The Zacks Rank system has a strong historical performance, with Rank 1 stocks averaging a +25% annual return since 1988 [7] - The Average Broker Recommendation for BWAY is also 1 (Strong Buy), indicating high optimism from the brokerage community regarding its near-term price performance [7] Group 3: Investment Strategy - The article suggests that BWAY may continue its price trend without reversal in the near future, making it a viable investment option [8] - In addition to BWAY, there are other stocks that meet the criteria of the "Recent Price Strength" screen, which can be considered for investment [8]

Core Viewpoint - Momentum investing focuses on following a stock's recent price trends, aiming to buy high and sell higher, with the expectation that established trends will continue [1] Company Summary: Brainsway Ltd. Sponsored ADR (BWAY) - BWAY currently holds a Momentum Style Score of A, indicating strong momentum characteristics [2] - The company has a Zacks Rank of 1 (Strong Buy), suggesting a favorable outlook based on historical performance of similar ranked stocks [3] - Over the past week, BWAY shares increased by 1.91%, outperforming the Zacks Medical - Products industry, which rose by 1.52% [5] - In the last month, BWAY's price change was 14.92%, significantly higher than the industry's 0.71% [5] - Over the past quarter, BWAY shares have risen by 23.23%, and over the last year, they have increased by 132.17%, compared to the S&P 500's gains of 6.49% and 25.94% respectively [6] - The average 20-day trading volume for BWAY is 111,929 shares, indicating a bullish sign with rising stock prices [7] Earnings Outlook - In the past two months, four earnings estimates for BWAY have been revised upwards, while none have been lowered, leading to an increase in the consensus estimate from $0.02 to $0.06 [9] - For the next fiscal year, three estimates have also moved upwards with no downward revisions [9] - These positive earnings revisions contribute to BWAY's strong performance and support its classification as a 1 (Strong Buy) stock with a Momentum Score of A [9]

Core Insights - BrainsWay Ltd. has appointed Richard A. Bermudes, M.D. as Chief Medical Officer effective September 1, 2024, succeeding Dr. Aron Tendler, M.D. who will continue to collaborate on strategic research projects [1][2] Company Overview - BrainsWay is a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, utilizing its proprietary Deep Transcranial Magnetic Stimulation (Deep TMS™) platform technology [3] - The company has obtained three FDA-cleared indications for Deep TMS, which include major depressive disorder, obsessive-compulsive disorder, and smoking addiction, supported by pivotal clinical studies demonstrating efficacy [3] - Founded in 2003, BrainsWay is committed to increasing global awareness and access to Deep TMS, with offices in Burlington, MA, and Jerusalem, Israel [3] Leadership and Expertise - Dr. Richard A. Bermudes brings over 20 years of experience in TMS and brain stimulation therapies, having co-founded a behavioral health care network and launched successful telehealth programs [2] - Dr. Bermudes is recognized as a leading clinician in the TMS field and has made significant academic contributions, including editing a notable book on clinical applications of transcranial magnetic stimulation [2]

Economic Policy and Interest Rates - Federal Reserve Chairman Jerome Powell indicated the first reduction in the benchmark interest rate since March 2020, with the current Fed fund rate at 5.25-5.5%, the highest in 23 years [1][3] - Powell emphasized that the timing and extent of rate cuts will depend on incoming data and the evolving economic outlook [3][4] - The Fed's previous aggressive rate hikes were necessary to combat rising inflation, which peaked at a 40-year high in June 2022 [3][5] Impact on Small-Cap Stocks - Small-cap stocks are expected to benefit the most from a potential rate cut, as they rely heavily on affordable credit for survival [7] - The pandemic severely impacted small businesses due to demand issues and supply chain disruptions, leading to a challenging operating environment [5][6] - The current high-interest rate regime has further strained small businesses, which typically operate on thin profit margins and struggle to pass on increased costs to consumers [6] Recommended Small-Cap Stocks - Five small-cap stocks with strong momentum and favorable Zacks Rank are identified: Fulcrum Therapeutics Inc. (FULC), Heritage Insurance Holdings Inc. (HRTG), Latham Group Inc. (SWIM), Seanergy Maritime Holdings Corp. (SHIP), and BrainsWay Ltd. (BWAY) [2][8] - Each of these stocks has shown positive earnings estimate revisions in the past 30 days and currently holds a Zacks Rank 1 (Strong Buy) [8] Company-Specific Insights - **Fulcrum Therapeutics Inc. (FULC)**: Focuses on developing treatments for genetically defined diseases, with an expected revenue growth rate of over 100% and earnings growth of 69.8% for the current year [10][12] - **Heritage Insurance Holdings Inc. (HRTG)**: Provides various insurance products, with expected revenue and earnings growth rates of 11.2% and 10.3%, respectively [13][14] - **Latham Group Inc. (SWIM)**: Designs and manufactures residential swimming pools, with expected revenue growth of 5.1% and earnings growth exceeding 100% [15][16] - **Seanergy Maritime Holdings Corp. (SHIP)**: A Capesize ship owner with expected revenue growth of 48.1% and earnings growth over 100% [17][18] - **BrainsWay Ltd. (BWAY)**: Develops neurostimulation treatments for mental health disorders, with expected revenue growth of 24.2% and earnings growth over 100% [19][21]

Shares of Brainsway Ltd. Sponsored ADR (BWAY) have gained 0.9% over the past four weeks to close the last trading session at $8.02, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $12.90 indicates a potential upside of 60.9%. The average comprises four short-term price targets ranging from a low of $11 to a high of $16, with a standard deviation of $2.17. While the lowest estima ...